MedPath

Diagnostic Imaging of Myeloma Bone Lesions

Not Applicable
Completed
Conditions
Multiple Myeloma
Interventions
Diagnostic Test: FDG-PET-CT
Diagnostic Test: NaF-PET-CT
Diagnostic Test: Whole-body MRI
Registration Number
NCT03147326
Lead Sponsor
Herlev Hospital
Brief Summary

The purpose of this study is to compare the current standard whole-body x-ray with the advanced imaging techniques FDG-PET-CT, NaF-PET-CT and whole-body MRI in the detection of myeloma bone lesions.

Detailed Description

Accurate detection of bone lesions in myeloma patients is essential for treatment planning and patient survival.

Newly diagnosed multiple myeloma patients can be enrolled in this study. All participants will at time of diagnosis undergo three project scans (FDG-PET-CT, NaF-PET-CT, whole-body MRI) as well as whole-body x-ray as part of clinical routine practice.

Experienced specialists in the field of radiology and nuclear medicine interpret the images. Each reader performs the evaluations blinded to other imaging results as well as to the patient's clinical information. The reader assesses whether myeloma indicative bone lesions are present in eight predefined skeletal body regions.

Endpoint is purely diagnostic.

Statistics:

Cochran's Q-test: to compare the proportion of patients with bone disease detected by the four scanning methods.

Two-sided ANOVA: to compare the average number of regions detected with bone disease by the four scanning methods.

Tukey's comparison test: to compare the difference between each pair of means.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
14
Inclusion Criteria
  • Newly diagnosed multiple myeloma (biopsy proven)
Exclusion Criteria
  • Prior malignancy
  • Are not able to undergo a MRI scan due to MRI contraindications (e.g. pacemaker)
  • Has any condition that places the subject at an unacceptable risk if he/she undergoes a diagnostic CT scan with iv. contrast (e.g. history of severe allergic reaction to the contrast agent)
  • Severe claustrophobia

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
FDG-NaF-MRIFDG-PET-CTAll participants will undergo three project scans/the following interventions: FDG-PET-CT NaF-PET-CT Whole-body MRI All participants will undergo a whole-body x-ray as part of clinical routine practice.
FDG-NaF-MRINaF-PET-CTAll participants will undergo three project scans/the following interventions: FDG-PET-CT NaF-PET-CT Whole-body MRI All participants will undergo a whole-body x-ray as part of clinical routine practice.
FDG-NaF-MRIWhole-body MRIAll participants will undergo three project scans/the following interventions: FDG-PET-CT NaF-PET-CT Whole-body MRI All participants will undergo a whole-body x-ray as part of clinical routine practice.
Primary Outcome Measures
NameTimeMethod
Bone metastases detection rate - a patient-based analysisThe three project scans will be performed once and as baseline scans within a maximum of 30 days from the performance of the whole-body x-ray. Image analyses and statistical tests will be done when all project scans have been performed

To compare the proportion of patients with bone disease detected by the four scanning techniques

Bone metastases detection rate - a region-based analysisThe three project scans will be performed once and as baseline scans within a maximum of 30 days from the performance of the whole-body x-ray. Image analyses and statistical tests will be done when all project scans have been performed

To compare the number of affected regions with bone disease detected by the four scanning techniques

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Radiology/Department of Nuclear Medicine

🇩🇰

Herlev, Denmark

© Copyright 2025. All Rights Reserved by MedPath